Antihypertensive effect of a dopamine beta hydroxylase inhibitor, bupicomide: A comparison with hydralazine

@article{Velasco1975AntihypertensiveEO,
  title={Antihypertensive effect of a dopamine beta hydroxylase inhibitor, bupicomide: A comparison with hydralazine},
  author={M. Velasco and C. A. Gilbert and C. Rutledge and J. McNay},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1975},
  volume={18}
}
The cardiovascular effects of a new antihypertensive drug, bupicomide, were compared with those of hydralazine in 6 patients with mild to moderate hypertension. The mean supine arterial pressure of patients was reduced 15.2 mm Hg by bupicomide (900 to 2,000 mg/day) and 15.7 mm Hg by hydralaslne (300 to 600 mg/day). Heart rate increased an average of 11.3 bpm during bupicomide and 14.5 bpm by hydralaine. Neither drug was associated with a postural decrease in mean arterial pressure. The heart… Expand
Effect of clonidine on sympathetic nervous activity in hydralazine-treated hypertensive patients
TLDR
The heart rate response to hydralazine was dose-related and the dose-response curve was shifted to the right by clonidine, and the increase in mean blood pressure induced by the cold pressor test was significantly attenuated byClonidine. Expand
Effect of propranolol on sympathetic nervous activity in hydrallazine-treated hypertensive patients.
TLDR
During the propranolol period, cold pressor test-induced increase of mean blood pressure was not reduced but propr ethanol blocked the increase of heart rate, which was not accompanied by a significant fall in heart rate. Expand
Oxdralazine, a New Peripheral Vasodilator, Combined With Propranolol and Hydrochlorothiazide: A Rational Approach to Antihypertensive Treatment
TLDR
The antihypertensive properties of each agent will be enhanced by a reduction in side effects by the associated drug, resulting in optimal blood pressure control, as well as the activation of the renin-angiotensin axis due to diuretics. Expand
Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients
TLDR
It is concluded that guanfacine is a useful agent to block a hydrallazine-induced increase in sympathetic nervous activity and to block an increase in plasma renin activity and urinary excretion of noradrenaline. Expand
Systemic and cardiac hemodynamic interactions between clonidine and minoxidil
TLDR
It is concluded that clonidine can be used as an alternative to β‐adrenergic blockers to counteract the increased sympathetic nervous activity minoxidil induces. Expand
Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.
TLDR
It is suggested that nepicastat functionally modulates sympathetic drive to cardiovascular tissues and may be of value in the treatment of cardiovascular disorders associated with overactivation of the sympathetic nervous system such as hypertension and congestive heart failure. Expand
Electrophysiologic effects of hydralazine on sinoatrial function in patients with sick sinus node syndrome.
TLDR
A minimal blood pressure response to hydralazine was associated with enhanced automaticity and merits clinical trial for treatment of sick sinus syndrome with concomitant hypertension. Expand
New inhibitors of dopamine β-hydroxylase
Abstract A32390A, 1,6-di-O-(2-isocyano-3-methylcrotonyl)- d -mannitol, obtained from fermentation broths of a species of Pyrenochaeta , inhibited DBH in vitro and lowered heart norepinephrine levelsExpand
Dopamine: a role in the pathogenesis and treatment of hypertension
  • M. Murphy
  • Medicine
  • Journal of Human Hypertension
  • 2000
TLDR
Evidence is emerging that abnormalities in DA production, or in signal transduction of the D1 receptor in renal proximal tubules, may result in salt retention and high blood pressure in some humans and in several animal models of hypertension. Expand
Clinical Pharmacokinetics of Hydralazine
TLDR
Since there is no clear-cut correlation between the plasma concentration of the drug and its effect upon blood pressure, there is at present no reason to routinely measure plasma levels of hydrallazine in treated hypertensive patients. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 57 REFERENCES
Combined Therapy with Vasodilator Drugs and Beta‐Adrenergic Blockade in Hypertension: A Comparative Study of Minoxidil and Hydralazine
TLDR
The role of vasodilators used in combination with beta-blockers and diuretics is suggested and the greater therapeutic efficacy of minoxidil is indicated. Expand
Effects of guancydine on systemic and renal hemodynamics in arterial hypertension
TLDR
Although mean arterial blood pressure decreased significantly in all patients, in only two did it reach normal levels, and Glomerular filtration rate and renal plasma flow remained unchanged while urinary sodium excretion diminished, suggesting a tubular effect. Expand
Observations on the Mechanism of Renin Release by Hydralazine in Hypertensive Patients
TLDR
In 20 patients with essential hypertension, hydralazine given intravenously caused significant increase in renal venous renin activity and in renin release estimated by the renal-systemic difference of ren in activity and renal plasma flow, and it is suggested that reninRelease following hydralazines may be caused by increased sympathetic discharge to the kidney caused reflexly by this agent. Expand
Pharmacologic properties of minoxidil: a new hypotensive agent.
TLDR
It is concluded that the hypotensive effect of this agent is due primarily to a vasodilator action, although attenuation of sympathetic vasoconstrictor nerve function may also contribute. Expand
Hemodynamic and therapeutic effects of guancydine in hypertension
TLDR
Although guancydine effectively reduced blood pressure, the side effects of fluid retention and sinus tachycardia preclude its long‐term use as a single agent. Expand
Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline).
Since the work of Goldblatt, Lynch, Hanzal, and Summerville which related renal ischemia causally to hypertension (1), it has seemed logical to use renal vasodilators in the treatment of theExpand
SCH 10595, an effective dopamine- -hydroxylase inhibitor and a hypotensive agent.
TLDR
The compound was found to lower blood pressure effectively in deoxycorticosterone acetate-hypertensive rats over a wide range of doses (30-300 mg/kg) and the blood pressure-lowering effect was well correlated with the reduction of endogenous NE levels in sympathetically innervated tissues. Expand
Adrenergic Component of Renin Release Induced by Vasodilating Antihypertensive Drugs in the Rat
TLDR
The propranolol inhibition suggests a beta-adrenergic component to this type of renin release and the potential for a clinically efficacious drug interaction. Expand
Renin Release in Patients with Benign Essential Hypertension
TLDR
In 16 of 28 patients with benign essential hypertension, reduction of mean arterial pressure by infusion of sodium nitroprusside caused significant increase in renin release estimated by the renal-systemic difference of renin activity and renal plasma flow, but no significant reninRelease occurred during reduction in pressure of comparable degree. Expand
Blood Pressure Decreased by Halobutylpicolinic Acid, an Inhibitor of Dopamine β-Hydroxylase
TLDR
Disulphiram, through its reduced metabolite diethyldithiocarbamate (DDC), is an effective inhibitor of dopamine β-hydroxylase3,4 and had been used successfully in the treatment of hypertension in man until 5-butylpicolinic acid was tried. Expand
...
1
2
3
4
5
...